Low-dose lactose in drugs neither increases breath hydrogen excretion nor causes gastrointestinal symptoms

Aliment Pharmacol Ther. 2008 Oct 15;28(8):1003-12. doi: 10.1111/j.1365-2036.2008.03815.x. Epub 2008 Jul 24.

Abstract

Background: Despite the reported tolerance to a low dose of lactose, many lactose malabsorbers follow a rigorous lactose-free diet also avoiding lactose-containing drugs. Up to now, only a few case reports have described the onset of gastrointestinal symptoms in lactose malabsorbers following the ingestion of these drugs. It has been suggested that capsules/tablets contain no more than 400 mg of lactose.

Aim: To evaluate breath H(2) excretion and intolerance symptoms after ingestion of a capsule containing 400 mg of lactose or placebo through a randomized, cross-over, double-blind, controlled study.

Methods: Seventy-seven lactose maldigesters with intolerance underwent two H2 breath tests with both 400 mg of lactose and 400 mg of placebo. Gastrointestinal symptoms occurring in the 8 h following the ingestion of different substrates were evaluated by a visual-analogue scale.

Results: Ingestion of 400 mg of lactose did not cause a significant difference in breath H2 excretion or in the severity of gastrointestinal symptoms compared to placebo.

Conclusion: In patients with lactase deficiency, drugs containing 400 mg of lactose or less can be used safely.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Abdominal Pain / etiology*
  • Adult
  • Aged
  • Aged, 80 and over
  • Breath Tests / methods
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Gastrointestinal Diseases / etiology*
  • Humans
  • Hydrogen / analysis
  • Lactose / adverse effects*
  • Lactose Intolerance / physiopathology*
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Statistics as Topic

Substances

  • Hydrogen
  • Lactose